Additionally, FDA-approved drug targets among these genes revealed 30 such targets, with CDK4 and FCGR1A identified as glioma-specific and ADORA3 as brain-specific, according to the Human Protein Atlas. The gene discussed is ADORA3; the disease is glioma.